Valacyclovir,
does it really help with Shorter lesion and symptom duration in recurrent herpes labialis?
research showsThe grade is C. Two large trials in the same GSK program shortened an episode by about one day, but Study 1 succeeded on symptom duration while Study 2 failed on lesion prevention, their different primary endpoints. No nonmanufacturer confirmation was identified, giving C with 54 points.
ads claimEvidence supports roughly one day less per episode when dosing begins at the first symptom. It does not support eliminating recurrence or reliably preventing lesion development.
Useful facts when choosing a product
- The tested regimen was valacyclovir 2 g at the prodrome or first symptom and another 2 g 12 hours later.
- Both trials were randomized, double-blind, placebo-controlled, and used an all-randomized analysis assigning 15 days to missing observations.
- Verdict 1147 is C with 44 points for recurrent herpes zoster eye disease, and verdict 1155 is B with 70 points for genital HSV-2 transmission; neither addresses acute cold-sore duration.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.oral-valacyclovir-started-at-the-first-symptom.oral.shorter-lesion-and-symptom-duration-in-recurrent-herpes-labialis.assess.placeboUnknown > oral valacyclovir started at the first symptom > Oral > Shorter lesion and symptom duration in recurrent herpes labialis > Association or change assessment > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Both trials were randomized, double-blind, and placebo-controlled, but they belonged to the same GSK development program and no nonmanufacturer confirmatory trial was identified. Ophthalmic-zoster verdict 1147 is C with 44 points, and genital-HSV transmission verdict 1155 is B with 70 points; both concern different indications.
Why this is classified as C (54)
The roughly one-day reduction was statistically clear, but evidence is limited to one manufacturer program and trial-specific primary-endpoint success was mixed, giving C with 54 points.
Counterpoint. This verdict is limited to early high-dose one-day episodic therapy and does not grade daily suppression or other herpes indications.
Rejudgment record. Cross-check applied — Episode shortening was observed only within the GSK program; Study 1 succeeded on duration while Study 2 failed on lesion prevention
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Shorter total episode duration | C | Two large trials found about one day less, without independent replication. |
| Prevention of lesion development | D | The prespecified primary endpoint in Study 2 was not significant. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Spruance et al. 2003 Study 1 | Multicenter randomized double-blind placebo-controlled trial | 902 randomized and 902 analyzed by intention to treat | GlaxoSmithKline development program with manufacturer-employed authors | Total cold-sore episode duration, the primary endpoint | Median 4.0 versus 5.0 days, difference -1.0, 95% CI -1.5 to 0.0, P=0.001; mean difference -1.1, 95% CI -1.6 to -0.6. | Pivotal positive primary-endpoint trial |
| Spruance et al. 2003 Study 2 | Separate multicenter randomized double-blind placebo-controlled trial | 954 randomized and 954 analyzed by intention to treat | Same GlaxoSmithKline development program | Lesion prevention was primary; episode duration was a separate efficacy endpoint | Mean 5.3 versus 6.3 days, difference -1.0, 95% CI -1.5 to -0.5, P<0.001; the lesion-prevention primary endpoint was not significant. | Within-program replication of shorter duration |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-01).
Final verification and publication gate: Codex · Evidence date: 2026-08-01 · Corrections: none
Cite this verdict
[Chamgap] Valacyclovir x shorter recurrent cold-sore episodes — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/valacyclovir-recurrent-cold-sore-episode-duration/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.